-
公开(公告)号:US12258597B2
公开(公告)日:2025-03-25
申请号:US16968452
申请日:2019-02-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Andrew Baik , Katherine Cygnar , Maria Praggastis
Abstract: Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.
-
公开(公告)号:US12215138B2
公开(公告)日:2025-02-04
申请号:US17528828
申请日:2021-11-17
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Andrew Baik , Katherine Cygnar , Christopher Schoenherr , Christos Kyratsous , Cheng Wang
Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.
-
公开(公告)号:US12252544B2
公开(公告)日:2025-03-18
申请号:US17056301
申请日:2019-05-17
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Katherine Cygnar , Andrew Baik , Christopher Schoenherr , Andrew J. Murphy
Abstract: Antibodies, portions, and fusion proteins thereof to CD63 are provided. Also provided are nucleic acid sequences encoding same. Also provided are compositions comprising and methods of using same, e.g., for treating a patient in need thereof.
-
公开(公告)号:US20240052051A1
公开(公告)日:2024-02-15
申请号:US18361367
申请日:2023-07-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Nicole Keating , Pascaline Aimé-Wilson , John Dugan , Min Gao , Robert Babb , Maria Praggastis , Katherine Cygnar , Bojie Zhang
CPC classification number: C07K16/2881 , A61P3/00 , C07K2317/565 , C07K2317/55 , C07K2317/622 , C07K2317/92 , C07K2317/14
Abstract: Provided, in part, are an anti-human transferrin receptor antigen-binding proteins and fusion proteins comprising an anti-human transferrin receptor antigen-binding proteins (e.g., in scFv, Fab or antibody format) which may be fused to a payload for delivery of the payload to a targeted tissue (e.g., past the blood-brain barrier and to the brain). Payloads include, for example, alpha-glucosidase (GAA) polypeptide. Methods for treating various diseases with such molecules, e.g., glycogen storage diseases, such as Pompe Disease, with the fusions are provided.
-
公开(公告)号:US20220195011A1
公开(公告)日:2022-06-23
申请号:US17528828
申请日:2021-11-17
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Andrew Baik , Katherine Cygnar , Christopher Schoenherr , Christos Kyratsous , Cheng Wang
Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.
-
公开(公告)号:US11129903B2
公开(公告)日:2021-09-28
申请号:US15202822
申请日:2016-07-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: A61K47/68 , C07K16/22 , C07K16/28 , C07K1/32 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46 , A61K39/00 , C12N9/64 , C07K16/32
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号:US20230345919A1
公开(公告)日:2023-11-02
申请号:US18320789
申请日:2023-05-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Alexander O. Mujica , Viktoria Gusarova , Cheng Wang , Christos Kyratsous , Terra Potocky , Katherine Cygnar , Joel H. Martin
IPC: A01K67/027 , A61K49/00 , C07K14/705 , C12N5/071 , C12N5/10
CPC classification number: A01K67/0278 , A61K49/0008 , C07K14/7056 , C12N5/0608 , C12N5/10 , A01K2207/15 , A01K2217/072 , A01K2227/105
Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
-
公开(公告)号:US11352446B2
公开(公告)日:2022-06-07
申请号:US16097108
申请日:2017-04-28
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Katherine Cygnar , Frank Delfino
Abstract: The present invention provides multispecific antigen-binding molecules and methods of making or selecting same. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号:US20220008548A1
公开(公告)日:2022-01-13
申请号:US17483588
申请日:2021-09-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: A61K47/68 , C07K16/22 , C07K16/28 , C07K16/32 , C12N9/64 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号:US11208458B2
公开(公告)日:2021-12-28
申请号:US16001717
申请日:2018-06-06
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Andrew Baik , Katherine Cygnar , Christopher Schoenherr , Christos Kyratsous , Cheng Wang
Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.
-
-
-
-
-
-
-
-
-